DIVI'S LABORATORIES LTD. - Updates

Further to our earlier communication dated 8th April, 2017 to the Stock Exchanges, we wish to update that the US-FDA has issued a Warning Letter for the company's Unit-II at Visakhapatnam. Divi's Laboratories responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed. As part of our commitments, we have also provided periodic updates to the US-FDA. In the Import Alert issued, US-FDA has exempted several products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. We will continue to supply these active ingredients to meet its obligations to our customers. Divi's Labs, along with external consultants and subject matter experts, are working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements. We will respond to this Warning Letter with a detailed plan within the stipulated time.